Why the study?
Does melagatran followed by oral ximelagatran prevent venous thromboembolism compared to enoxaparin in patients undergoing total hip or knee replacement?
Does melagatran followed by oral ximelagatran prevent venous thromboembolism compared to enoxaparin in patients undergoing total hip or knee replacement?
Postoperative melagatran followed by oral ximelagatran resulted in a marginally higher rate of venous thromboembolism compared to preoperative enoxaparin after major orthopedic surgery, with comparable bleeding.
Answers are grounded in this paper and cite their sources.
Ximelagatran is not noninferior to enoxaparin for VTE prevention after major orthopedic surgery; challenges its adoption as an oral alternative.
We evaluated whether a postoperative regimen with melagatran followed by oral ximelagatran, two new direct thrombin inhibitors, was an optimal regimen for thromboprophylaxis in major orthopaedic surgery. In a double-blind study, 2788 patients undergoing total hip or knee replacement were randomly assigned to receive for 8 to 11 days either 3 mg of subcutaneous melagatran started 4-12 h postoperatively, followed by 24 mg of oral ximelagatran twice-daily or 40 mg of subcutaneous enoxaparin once-daily, started 12 h preoperatively. Ximelagatran was to be initiated within the first two postoperative days. The primary efficacy endpoint was venous thromboembolism (deep-vein thrombosis detected by mandatory venography, pulmonary embolism or unexplained death). The main safety endpoint was bleeding. Venous thromboembolism occurred in 355/1146 (31.0%) and 306/1122 (27.3%) patients in the ximelagatran and enoxaparin group, respectively, a difference in risk of 3.7% in favour of enoxaparin (p = 0.053). Bleeding was comparable between the two groups.
No takes yet. Share an insight, caveat, or question.
Agnelli et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: